Moore Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Moore Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-40,000	Closed	-$5.51M	–	528
2024 Q2	$5.51M	Buy	+40,000	New	+$5.49M	0.1%	197
2023 Q4	–	Sell	-55,000	Closed	-$6.19M	–	503
2023 Q3	$6.19M	Buy	+55,000	New	+$5.79M	0.12%	132
2021 Q1	–	Sell	-96,075	Closed	-$9.21M	–	746
2020 Q4	$9.21M	Buy	+96,075	New	+$9.28M	0.1%	151
2019 Q2	–	Sell	-54,213	Closed	-$4.78M	–	359
2019 Q1	$4.78M	Buy	54,213 +10,422	+24%	+$871K	0.15%	154
2018 Q4	$3.13M	Buy	+43,791	New	+$4.2M	0.12%	122
2016 Q1	–	Sell	-130,000	Closed	-$7.35M	–	309
2015 Q4	$7.35M	Buy	130,000 +95,000	+271%	+$4.83M	0.23%	118
2015 Q3	$1.39M	Sell	35,000 -20,000	-36%	-$967K	0.07%	228
2015 Q2	$2.63M	Buy	+55,000	New	+$2.33M	0.06%	283

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's NBIX Position: Q3 2024 in Review

Moore Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 40,000 shares — an estimated $5.51M sold.

Moore Capital Management first reported a position in NBIX in Q2 2015 and held it in 8 quarters. The position peaked at $9.21M in Q4 2020. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

Moore Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
Moore Capital Management sold 40,000 Neurocrine Biosciences shares in Q3 2024, an estimated $5.51M.
Moore Capital Management first reported a position in Neurocrine Biosciences in Q2 2015 and held it in 8 quarters.
Moore Capital Management's Neurocrine Biosciences position peaked at $9.21M in Q4 2020.
574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.